These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 22193723)
1. Application of vitamin D and derivatives in hematological malignancies. Kim M; Mirandola L; Pandey A; Nguyen DD; Jenkins MR; Turcel M; Cobos E; Chiriva-Internati M Cancer Lett; 2012 Jun; 319(1):8-22. PubMed ID: 22193723 [TBL] [Abstract][Full Text] [Related]
3. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. Ravandi F; Talpaz M; Estrov Z Clin Cancer Res; 2003 Feb; 9(2):535-50. PubMed ID: 12576416 [TBL] [Abstract][Full Text] [Related]
4. Current progress in using vitamin D and its analogs for cancer prevention and treatment. Cheung FS; Lovicu FJ; Reichardt JK Expert Rev Anticancer Ther; 2012 Jun; 12(6):811-37. PubMed ID: 22716497 [TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. Martinelli G; Iacobucci I; Paolini S; Ottaviani E Clin Adv Hematol Oncol; 2008 Apr; 6(4):303-10. PubMed ID: 18496498 [TBL] [Abstract][Full Text] [Related]
6. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836 [TBL] [Abstract][Full Text] [Related]
7. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies. Sankhala K; Giles FJ Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945 [TBL] [Abstract][Full Text] [Related]
8. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. Karp JE; Lancet JE Cancer Invest; 2007 Sep; 25(6):484-94. PubMed ID: 17882662 [TBL] [Abstract][Full Text] [Related]
9. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer]. Usui N Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247 [No Abstract] [Full Text] [Related]
13. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases. Chase A; Cross NC Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463 [TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy in elderly patients with hematological malignancies]. Ohnishi K Gan To Kagaku Ryoho; 2011 Oct; 38(10):1586-90. PubMed ID: 21996952 [TBL] [Abstract][Full Text] [Related]
15. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies. Karp JE; Lancet JE Ann Hematol; 2004; 83 Suppl 1():S87-8. PubMed ID: 15124688 [TBL] [Abstract][Full Text] [Related]
16. Emerging targets for hematological malignancies. Cilloni D; Frassoni F; Saglio G Curr Opin Drug Discov Devel; 2010 Sep; 13(5):548-58. PubMed ID: 20812146 [TBL] [Abstract][Full Text] [Related]
17. [Molecular aspects of antineoplasic action of vitamin D]. Bohl LP; Liaudat AC; Picotto G; Tolosa de Talamoni NG Rev Fac Cien Med Univ Nac Cordoba; 2008; 65(1):17-22. PubMed ID: 20803935 [TBL] [Abstract][Full Text] [Related]
18. Management of hematological malignancies during pregnancy. Rizack T; Mega A; Legare R; Castillo J Am J Hematol; 2009 Dec; 84(12):830-41. PubMed ID: 19844988 [TBL] [Abstract][Full Text] [Related]
19. Vitamin D analogs in cancer prevention and therapy. Reichrath J; Tilgen W; Diedrich K; Friedrich M Anticancer Res; 2006; 26(4A):2511-4. PubMed ID: 16886658 [TBL] [Abstract][Full Text] [Related]
20. Application of vitamin D and vitamin D analogs in acute myelogenous leukemia. Cao H; Xu Y; de Necochea-Campion R; Baylink DJ; Payne KJ; Tang X; Ratanatharathorn C; Ji Y; Mirshahidi S; Chen CS Exp Hematol; 2017 Jun; 50():1-12. PubMed ID: 28174131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]